Chicago, IL and Salt Lake City, January 8, 2023: Biotech Showcase, 2023 (BTS) is THE investor conference for companies who are not customers of bulge bracket banks, ie, JP Morgan. These mid-cap, small-cap, and early-stage companies rely on their in-person presentations to speak to the investment world in one efficient location. It is our strong conviction that while most investors attending a presentation will not invest in the company, all companies deserve to have real investors attend their presentations. Investors attend the conferences free of charge. We hope that every one of the 1,000+ registered investors will enjoy their lunches and peer networking–and attend 5 company presentations.
Of course, we’re biased. We’re a marketing firm.
Content Carnivores is also a long-time Silver Sponsor at the Biotech Showcase™. We applaud the ongoing success of Sara Demy and the super-talented team she has in place. We are proud to announce that we have 5+ clients who will be presenting and/or meeting investors in SF this week.
Who is Content Carnivores?
First of all, we love science and brilliance in all categories. And we are enthusiastic about our work, our clients and the industry. As such, Content Carnivores works with biotech and medtech (as well as others) companies who are solving some of the toughest problems in healthcare. Their need to communicate to strategic audiences is greater today than ever. We provide a combination of intelligent tech, category expertise, and elbow grease. In the past 10 years we have helped 1,000+ Companies strategize, create, package and distribute their stories and succeed. And yes, we have excellent case studies with stats that matter.
A Personal Note from Iron Chef, Chelli
JPM Week, or as we prefer to call it, BTS Week, is a busy, noisy, exhausting time next week but I have to admit, I just love it! We’re sponsors at the Biotech Showcase so much of our time is there. Please message me or Jeff if you’d like to learn more or meet one of our companies!
Outstanding Presentations Worth Attending
Pacylex - leukemia/AML - Oncology
Presenting at the Biotech Showcase on Tuesday, January 10, 2023, 10:45 AM PST.
Pacylex has been developing a gem that is now at a significant inflection point. PCLX-001 is a first-in-kind, small molecule with a novel mechanism of action believed to play a significant role in the development of certain types of blood cancers and solid tumors. They have met numerous clinical and organizational milestones and are now raising their Series B.
Infectious Diseases - Vaccines
For generations, antibiotics and vaccines were the answer to bacterial infections, infectious diseases and other life-threatening diseases. Now, new platforms generate amazing ways to fight.
GeoVax's vaccine platform has proven preclinical efficacy in five infectious diseases (Lassa, Ebola, Marburg, Zika, and HIV) and has shown an excellent safety profile in their HIV human clinical trials to date. This builds an excellent scientific foundation on which they are using the MVA platform to build an immuno-oncology program. GeoVax does not deal with live viruses. Instead, they utilize a VLP (virus like particle) tech with so much upside - I could write a book on this company! Here’s a little deeper into their science.
Presenting at the Biotech Showcase on Monday, January 9, 2023 5 PM PST.
Gene Therapy
Carmine Therapeutics: Gene Therapy 3.0
Presenting at the Biotech Showcase on Tuesday, January 10, 2023 10 AM PST.
Carmine Therapeutics is developing allogeneic, redosable, non-viral gene therapies to treat diseases for which a high unmet medical need exists. The company’s technology harnesses the natural properties of human red blood cells (RBCs) to produce extracellular vesicles (EVs), allowing the delivery of large payloads of genetic material, resulting in high-amplitude, durable transgene expression to replace missing or mutated genes found within the patient. The initial focus is on ocular diseases, including Stargardt disease with plans to expand to cystic fibrosis and neurological diseases in the future.
Content Carnivores is dedicated to delivering the highest standards of ideas and writing so that greatness finds its widest audience to deliver on business objectives. Headquartered in Chicago with a satellite office in Utah. We leverage a proprietary technology platform that dramatically speeds up the discovery, creation, and publication of high-quality content to help brands and businesses amplify awareness and establish thought leadership to their target audiences.
Our proprietary IR Comm program fills gaps Marketing, PR and IR firms can't /don't/won't reach at a time when strategic communications are more important than ever.
The company founders built the technology platform and designed proprietary service programs, having previously run content marketing and advertising programs at the largest global agency in the world as well as for other global content marketing pioneers. Current clients include leaders in healthcare, marketing, medical devices, financial services and technology.
Disclaimer: Please note that all of the above companies are clients of our marketing services. We are not broker/dealers and do not make any investment recommendations. Here's our full disclaimer.
